Management ChangeAug 3, 2026, 05:36 PM
Vivos Therapeutics Appoints Roman Franklin as New CFO
AI Summary
Vivos Therapeutics, Inc. announced the resignation of Bradford Amman as Chief Financial Officer and Secretary, effective July 31, 2026. Mr. Amman will transition to a non-executive role for 90 days as principal accounting officer, followed by a 180-day advisory period, receiving compensation including salary, advisory fees, and equity grants. Concurrently, Roman Franklin was appointed as the new CFO, effective July 31, 2026. Mr. Franklin, provided through a Master Services Agreement with The CFO Portal, LLC, brings over 20 years of finance and operations leadership experience to the company.
Key Highlights
- Bradford Amman resigned as CFO and Secretary of Vivos Therapeutics, effective July 31, 2026.
- Amman will serve as principal accounting officer for 90 days, then as an advisor for 180 days.
- He will receive his current base salary during the transition period and a $13,333 monthly advisory fee.
- Amman will be granted 250,000 fully vested common stock shares and options for 150,000 shares.
- Roman Franklin, age 42, was appointed as the new Chief Financial Officer, effective July 31, 2026.
- Franklin has over 20 years of finance and operations leadership experience in public and private companies.
- Vivos Therapeutics entered a Master Services Agreement with The CFO Portal, LLC for CFO services.
- The agreement with CFO Portal has an initial term of 12 months.
Price Impact
More from VVOS